Sanofi-owned Genzyme said today it will build a new $80 million downstream processing facility for its Fabry disease treatment adjacent to its new Fabrazyme cell culture manufacturing site in Framingham, MA.
Sanofi-owned Genzyme said today it will build a new $80 million downstream processing facility for its Fabry disease treatment adjacent to its new Fabrazyme cell culture manufacturing site in Framingham, MA.
